Renal involvement in systemic lupus erythematosus: the present views of its pathogenesis and clinical manifestationsand the approaches to its treatment
https://doi.org/10.14412/1996-7012-2008-483
Abstract
The paper deals with the pathogenesis, clinical picture, and treatment of renal involvement in patients with systemic lupus erythematosus (SLE). It is noted that at the onset of the disease, there are signs of renal involvement in 25-50% of patients with SLE; they are further detectable in almost 60% of adults and in 80% of children. The types of renal lesion are described in SLE.
The pathogenesis of SLE as a whole is examined on a model of lupus nephritis. The morphological classification of lupus nephritis, the specific features of major nephrological syndromes, and the clinical types (active and inactive) are given. Treatment policy is stated to depend on the activity of the disease, the clinical and morphological type of lupus nephritis. Current immunosuppressive therapy can reduce the proportion of patients with terminal renal failure on the one hand and shows the prognostic value of renal involvement for the course of the disease as a whole, on the other.
New immunological involvement strategies are associated with total irradiation of the lymphoid system or marrow, followed by stem cell grafting.
The pathogenesis of SLE as a whole is examined on a model of lupus nephritis. The morphological classification of lupus nephritis, the specific features of major nephrological syndromes, and the clinical types (active and inactive) are given. Treatment policy is stated to depend on the activity of the disease, the clinical and morphological type of lupus nephritis. Current immunosuppressive therapy can reduce the proportion of patients with terminal renal failure on the one hand and shows the prognostic value of renal involvement for the course of the disease as a whole, on the other.
New immunological involvement strategies are associated with total irradiation of the lymphoid system or marrow, followed by stem cell grafting.
References
1. <div><p>Тареева И.Е., Краснова Т.Н. Поражение почек при системной красной волчанке. Нефрология. Руководство для врачей. Под ред. И.Е.Тареевой. М.: Медицина, 2000.</p><p>Vu T.V., Escalante A. A comparison jf quality of life of patients with systemic lupus erythematosus. J Revmatol 1999; 26: 2595-601.</p><p>Trager J., Ward M.M. Mortality and causes of death in systemic lupus erythematosus. Current Opinion in Rheumatology 2001; 13: 345-51.</p><p>Cervera R., Khamashta M.A., Font J. Morbidity and mortality in systemic lupus ery-thematosus during a 10-year period. Medicine 2003; 82(5): 299-308.</p><p>Камерон Дж.С. Волчаночный нефрит и его ведение в 2001 г. В кн.: Успехи нефрологии. Под ред. Н.А. Мухина. М.: Русский врач, 2001; 145-64.</p><p>Тареева И.Е., Шилов Е.М, Краснова Т.Н. и др. Волчаночный нефрит в середине ХХ и начале ХХI века. Тер арх 2001; 6: 5-10.</p><p>Метелева Н.А., Козловская Н.Л. Поражение почек при антифосфолипидном синдроме. Тер арх 2004; 9: 91-6.</p><p>Мухин Н.А., Козловская Л.В., Козловская Н.Л. и др. Первичный антифосфолипидный синдром - «венозный» и «артериальный» варианты течения. В кн.: Клинические разборы. Внутренние болезни. Под ред. Н.А. Мухина. М.: Литтерра, 2005; 261-77.</p><p>Стенина О.А., Сорокин Е.В., Фомичева О.А. и др. Распространенность и факторы риска атеросклероза у больных системной красной волчанкой. Кардиология 2005; 11: 105-8.</p><p>Као А.Н., Sabatine J.M., Manzi S. Update on vascular disease in systemic lupus erythe-matosus. Current Opinion in Rheumatology 2003; 15: 519-27.</p><p>Kohler H.P., Futers T.S., Grant P.J. Prevalence of three common polymorphisms in the A-subunit gene of factor XIII in patients with coronary artery disease. Thromb Haemost 1999; 81(4): 511-5.</p><p>Ward M.M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis and rheumatism 1999; 42(2): 338-46.</p><p>Шилов Е.М. Волчаночный нефрит: стратегия и лечение. Тер арх 2006; 5: 76-85. D'Crus. Mycophenolate mofetil of systemic vasculitis. Lupus 2005; 14: 55-7.</p><p>Chan T., Tse K., Tang C. et al. Long-term study of micophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. Am J Soc Dis 2005; 16: 1076-84.</p><p>Cune W. Mycophenolate mofetil for lupus nephritis. N Engl J Med 2005; 353: 2282-4.</p></div><br />
Review
For citations:
Krasnova TN, Krasnova TN. Renal involvement in systemic lupus erythematosus: the present views of its pathogenesis and clinical manifestationsand the approaches to its treatment. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2008;2(3):18-21. (In Russ.) https://doi.org/10.14412/1996-7012-2008-483
Views:
6307
Email this article 